Kineta secures undisclosed NIAID funding to advance IRF-3–based antivirals against Zika
Kineta, a Seattle biotech, received undisclosed NIAID funding to expand research on its Innate Immune Antiviral program targeting Zika by leveraging IRF-3–based broad-spectrum antivirals that showed efficacy against other flaviviruses like Dengue and West Nile.